Half Of 1st Approved Generics Do Not Launch Due To Part D Formulary Obstacles, AAM Says

Medicare Part D program should place generics on tiers separate from brand drugs and create a dedicated tier for specialty generics and biosimilars, AAM advocates in white paper.